Epigral Limited company name has scheduled a one-on-one meeting with VVD Asset Managers for August 3, 2026, in Ahmedabad. The engagement is designed to facilitate direct dialogue between the company’s management and institutional investors regarding business performance and strategy. This interaction supports transparency and keeps stakeholders informed about the company's operational trajectory without disclosing any unpublished price-sensitive information.

The meeting was intimated to the National Stock Exchange of India Limited and BSE Limited on July 30, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Gaurang Trivedi, Company Secretary and Compliance Officer of Epigral Limited, signed the disclosure. The schedule remains subject to change due to exigencies on the part of either the institutional investors or the company.

Meeting Details

Participants are advised that the latest Earnings Presentation and Corporate Presentation, which may be discussed during the session, are already available on the company’s website at www.epigral.com . Epigral Limited explicitly stated that no unpublished price-sensitive information will be shared or discussed during the meeting. This ensures compliance with regulatory standards while allowing investors to review publicly available data.

Investor Relations Context

Such one-on-one meetings are a standard component of corporate governance and investor relations protocols for listed entities in India. They allow asset managers like VVD Asset Managers to gain deeper insights into the company’s strategic direction, operational metrics, and market positioning beyond what is captured in periodic financial filings. For shareholders, these interactions signal active engagement with institutional capital providers, which can influence long-term investment decisions and market confidence in the firm’s management team.

Epigral Limited reported a standalone net profit of ₹99.18 crore for the quarter ended June 30, 2026 (Q1FY27), marking a 38% decline from ₹160.41 crore in the corresponding period of FY26. The drop in profitability stems from increased cost of materials consumed and the absence of a significant one-time tax benefit recorded in the prior year, even as revenue from operations grew 16% to ₹705.36 crore. Consolidated net profit stood at ₹99.74 crore, compared to ₹160.69 crore in Q1FY26. EBITDA for the quarter came in at ₹1.8B versus ₹1.6B in the year-ago period, while EBITDA margin contracted to 25.39% from 27% YoY.

The Board of Directors approved the unaudited financial results on July 27, 2026, pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. M/s. S R B C & CO LLP, the statutory auditors, issued a limited review report on the figures. The results were prepared in accordance with Ind AS 34 "Interim Financial Reporting" under Section 133 of the Companies Act, 2013.

Financial Performance

Revenue from operations rose to ₹705.36 crore in Q1FY27 from ₹606.54 crore in Q1FY26. However, total expenses increased to ₹576.28 crore from ₹508.06 crore during the same period. The cost of materials consumed surged to ₹430.18 crore from ₹318.19 crore, reflecting higher input costs in the Chloro Alkali & Derivatives segment. Finance costs decreased significantly to ₹7.22 crore from ₹23.37 crore, providing some relief to the bottom line.

The profit before tax rose 25% to ₹133.18 crore from ₹106.73 crore. However, the tax expense for Q1FY27 was ₹34.00 crore, compared to a net tax credit of ₹53.68 crore in Q1FY26. The prior year's credit included a one-time deferred tax credit of ₹80.87 crores arising from the remeasurement of deferred tax liabilities after the company opted for the reduced tax rate under Section 115BAA of the Income-tax Act, 1961.

What the Numbers Show

The divergence between the 25% rise in pre-tax profits and the 38% fall in net profit highlights the impact of non-recurring items on Epigral's bottom line. Excluding the one-time deferred tax credit of ₹80.87 crores recognized in Q1FY26, the underlying tax burden has normalized. The current quarter's effective tax rate is approximately 25.5%, aligning with the standard corporate tax regime, whereas the prior year benefited from a massive accounting adjustment. The contraction in EBITDA margin to 25.39% from 27% further reflects the pressure from higher input costs, even as EBITDA in absolute terms improved. This suggests that while operational profitability is expanding due to revenue growth outpacing expense increases, headline net profit comparisons are distorted by the prior year's exceptional tax credit.

Strategic Developments

Epigral incorporated a wholly owned subsidiary, Epigral Advanced Material Limited, on July 07, 2026, aimed at manufacturing chemicals. Additionally, the company continues its investment in renewable energy through Pro-Zeal Green Power Ten Private Limited, where it holds a 26% equity stake and has invested ₹2.13 crores in optionally convertible debentures. The associated wind-solar hybrid power plant in Gujarat is expected to commence operations in the near future.